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Active surveillance for lyssaviruses was conducted among populations of bats in the Philippines. The pres-
ence of past or current Lyssavirus infection was determined by use of direct fluorescent antibody assays
on bat brains and virus neutralization assays on bat sera. Although no bats were found to have active
infection with a Lyssavirus, 22 had evidence of neutralizing antibody against the Australian bat lyssavirus
(ABLV). Seropositivity was statistically associated with one species of bat,  Miniopterus schreibersi.
Results from the virus neutralization assays are consistent with the presence in the Philippines of a natu-
rally occurring Lyssavirus related to ABLV.
uring the past decade, bats have been associated with a
number of newly recognized zoonotic agents, including
Hendra, Menangle, Nipah, and Ebola viruses and the Austra-
lian bat lyssavirus (ABLV) (1-5). ABLV and classic  Rabies
virus (RABV) are members of the genus  Lyssavirus. These
viruses are genetically similar and cause indistinguishable
clinical syndromes in infected mammals. In the United States,
where endemic canine rabies has been eliminated through vac-
cination and animal control, bat-associated variants of RABV
have accounted for 24 (75%) of the 32 cases of human rabies
reported since 1990 (6,7). Of the nearly 30,000 laboratory-
confirmed cases of animal rabies reported worldwide in 1997,
4% were in bats (8). However, not all countries are included in
this survey, and surveillance methods vary between countries
included in the compilation. Bat-associated rabies cases in
humans are likely underreported in this global surveillance
report because not all countries report a history of animal
exposure or type the virus variants. 
In the Philippines, where approximately 350 cases of
human rabies are diagnosed clinically each year, attribution of
the animal associated with the exposure is based on history
(8). Previous surveys for rabies in Philippine bats conducted in
the 1950s and 1960s failed to document active rabies infection
in the animals examined (9,10). The increasingly recognized
role of bats in the global maintenance and transmission of viral
infections, the recent discovery of rabies among bats in Austra-
lia, and the unknown proportion of rabies cases in Southeast
Asia potentially attributable to bats prompted this initiation of
active surveillance for lyssaviruses in Philippine bat populations.
Methods
Collection of Specimens
From June 25 through September 11, 1998, bats were non-
randomly collected from multiple sites on six different islands
in the Philippines (Figure). Sites were chosen on the basis of
local reports of known bat colonies or after investigation of
likely habitats, such as caves, church belfries, or orchards
(11,12). Insectivorous and small fruit bats were captured dur-
ing the day in fine-mesh, long-handled butterfly nets and at
night in mist nets. Larger fruit bats were also obtained from
hunters. Thick leather gloves were worn when captured bats were
transferred into individual muslin pouches for transportation. 
Bats were anesthetized by a 0.05- to 0.1-mg intramuscular
injection of ketamine hydrochloride and euthanized by intra-
cardiac exsanguination. All blood was transferred from the
collecting syringe into serum separator tubes and refrigerated
until centrifugation. Serum was decanted into individual
screw-topped vials and frozen at –20°C. Bats were identified
to species by using a key based on gross morphology (13). The
brains of all bats were removed surgically and frozen in indi-
vidual containers. Additional organs (e.g., liver, spleen, and
lungs) were also harvested from each bat and stored either in a
freezer at -70￿C or in 20% formalin for future studies. Car-
casses of representative specimens were stored in formalin for
archival purposes. 
Direct Fluorescent Antibody (DFA) Testing of Brains
At the Research Institute for Tropical Medicine in Manila,
the bat brains were thawed and multiple impressions were pre-
pared for DFA testing (14). Microscope slides were fixed in
cold acetone and allowed to dry. Brain impressions were
stained with fluorescein isothiocyanate (FITC)-conjugated
anti-rabies monoclonal antibodies (Fujirebio Diagnostics,
Malvern, PA) and examined under a fluorescent microscope
for Lyssavirus antigens. This monoclonal antibody preparation
reliably detects infection with all known lyssaviruses, includ-
ing both classic RABV and ABLV (5,15-17).
Serologic Testing for Neutralizing Antibodies
At the Centers for Disease Control and Prevention (CDC),
the presence of virus-neutralizing antibodies was determined
by a modification of the rapid fluorescent focus inhibition test
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(RFFIT) (18). Two different challenge viruses were used: the
routine rabies challenge virus standard (CVS-11) and an iso-
late of ABLV adapted to cell culture. Viruses and bat serum
samples were diluted with Eagle minimum essential medium
containing 10% fetal calf serum (EMEM10) and antibiotics to
reduce bacterial and fungal contamination as described (18).
EMEM10 was also used in the growth of murine neuroblas-
toma (MNA) cells, which were used to propagate and grow
sufficient quantities of each virus, and in the modified RFFIT
assays. CVS-11 was obtained from stocks at CDC. The ABLV
isolate (Saccolaimus flaviventris [sm4068]; Australian Animal
Health laboratory, Geelong, Australia) was originally obtained
from an insectivorous bat in Australia and was amplified by
passage in BHK and MNA cells at CDC. 
All bat serum samples were thawed and placed in a 56￿C
water bath for 30 minutes to inactivate complement. Serum
samples were then diluted to 1:10 if possible. Samples with
insufficient volume were screened at a higher dilution. The
RFFIT was conducted by using Lab-Tek 8-well glass slides
with covers (Nalge Nunc International, Naperville, IL). Sera
were screened for antibody by incubating 100 mL of diluted
serum with 100 mL of ABLV or CVS-11 that had been diluted
to contain approximately 100 infectious units when incubated
for 90 minutes at 37°C in a CO2 incubator. MNA cells
(approximately 75,000 cells/200  mL) were added to each
serum-virus mixture, and the incubation was continued. After
48 hours, culture medium was removed, and the slides were
fixed in acetone, air-dried, and stained for residual virus with
FITC-conjugated anti-rabies monoclonal antibodies. A sample
was defined as positive for neutralizing antibody if at least a
90% reduction in infectious centers was observed relative to
the positive control. All positive samples were retested at
increasing dilutions to estimate endpoint antibody titers. Stan-
dard human rabies immune globulin (HRIG) diluted to contain
2 IU/mL antibodies was used as a positive serum control for
all tests. The titer of HRIG ranged from 1:125 to 1:625 against
both ABLV and CVS-11. 
Results from the serologic testing were used to detect pat-




Of the 821 bats collected, all but three were identified to
species (Table 1). The collection resulted in 14 different spe-
cies of both insectivorous and frugivorous bats representing
five of the six families of Chiroptera believed to be present in
the Philippines. Fifty-one percent of the bats were female,
including 22 that were pregnant and 6 that were suckling
infants. All bats appeared to be healthy except one with an
enlarged spleen and three that appeared to have a mange-like
condition. Since some bats died during collection and process-
ing, serum could not be collected from all the bats.
DFA Testing of Brains
Brains from all 821 bats were tested for the presence of RABV
antigen by DFA. None of the bats had detectable antigen consis-
tent with an active infection with rabies or a related Lyssavirus. 
Serologic Testing for Neutralizing Antibodies
Of the 821 bats collected, 231 had sufficient volume and
quality of serum to be diluted to 1:10 and successfully
Figure. Collection sites for bats used in active surveillance of lyssavi-
ruses in the Philippines.RESEARCH
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screened at 1:20, after being combined with the challenge
virus (Table 2). An additional 43 specimens were screened at
higher dilutions. Remaining samples contained insufficient
volumes or could not be tested because of hemolysis. 
Of the 231 bat sera tested, 22 (9.5%) were positive for neu-
tralizing antibodies against ABLV. Antibody titration studies
demonstrated decreasing percent neutralization at progres-
sively higher serum dilutions. Of those 22 bat sera, 8 demon-
strated no virus neutralization at the next highest dilution
tested; 8 demonstrated some neutralization as dilute as 1:40; 3
had some at 1:80; 2 had some at 1:160; and 1 had evidence of
some neutralization at a dilution of 1:320. When the strict def-
inition of 90% to be considered positive was used, only two
bat sera remained positive at the 1:40 dilution. This dilution is
the equivalent of 0.6 IU/mL antibody. Five of those 22 sam-
ples were also positive when tested against CVS-11. Only 1 of
the 209 bat sera that was negative when tested against ABLV
was positive when tested against CVS-11. 
The 22 bats with neutralizing antibodies against ABLV
included six different species collected from four islands
(Table 3). No location was significantly associated with bat
sera that tested positive. Antibody-positive bats were evenly
dispersed throughout the collection period (July 5 through
September 5). Only 32% of the antibody-positive bat sera
were obtained from females. That proportion was not statisti-
cally significant. The only significant association in the analy-
sis was that a single species had a statistically greater
proportion of samples testing positive. Thirty-six percent of
the 11 Mineopterus schreibersi (Schreiber’s long-fingered bat)
tested positive (p=0.01). 
The data analysis was repeated with a less strict case defi-
nition of 75% reduction in infectious centers relative to the
positive control and including the 43 additional samples that
could only be screened at higher dilutions. When these criteria
were used, 53 (19%) of 274 bat sera tested were positive. The
two samples with the highest positive endpoint titers in the ini-
tial analysis remained highest, but now at a 1:80 dilution.
Although additional species would have been identified as
having neutralizing antibodies,  M. schreibersi remained the
only species with a statistically significantly greater proportion
of serum samples positive for neutralizing antibody. 
Discussion
This study presents evidence of neutralization of ABLV by
serum from Philippine bats. This neutralizing activity corre-
lated with the ability to neutralize RABV (CVS-11) and
titrated steadily with serial dilutions of the serum. These find-
ings are consistent with the presence of naturally occurring
antibodies against a Lyssavirus related to ABLV in the Philip-
pine bat populations studied. 
Lyssaviruses are classified into groups on the basis of their
relative pathogenicity, their binding affinity to specific mono-
clonal antibodies, and their nucleic acid sequences. There are
seven putative genotypes that have been aggregated into two
basic groups on the basis of their overall phylogenetic related-
ness (19). Phylogroup I includes RABV (genotype 1), Duven-
hage virus (DUVV) (genotype 4),  European bat lyssavirus
(EBLV) 1 (genotype 5), EBLV-2 (genotype 6), and ABLV
(genotype 7). Phylogroup II includes Lagos bat virus (LBV)
(genotype 2) and Mokola virus (MOKV) (genotype 3). Anti-
bodies to viruses within one phylogroup should cross-neutral-
ize viruses of that same phylogroup. The ability to cross-
neutralize is directly proportional to the relative nucleotide and
amino acid homogeneity between the two viruses being
Table 1. All bats caught on six islands in the Philippines and tested for Rabies virus antigen by direct fluorescent-antibody assay, June 25 to Sep-
tember 11, 1998
Bat species Island of origin
Luzon Bohol Boracay Mindanao Mindoro Negros 
Saccolaimus saccolaimus 53 54
Taphozous melanopogan 96
Megaderma spasma 16
Hipposideros diadema 16 1 2
Rhinolophus spp. 6 3
Mineopterus schreibersi 14
Philetor brachypterus 24
Scotophilus kuhlii 105 1 95
Cynopterus brachyotis 3 12 1 4
Eonycteris spelaea 1 6 2 1
Macroglossus minimus 4 3 3
Ptenochirus jagori 36 4 6
Pteropus hypomelanus 27
Rousettus amplexicaudatus 1 112 98 6 1 1Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 261
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compared (19). In another study of Nigerian fruit bats, 2 of 50
serum samples had neutralizing antibodies against CVS-11 but
failed to neutralize DUVV (20). In the bats in this study, no
cases of active  Lyssavirus infection were discovered from
which nucleotide and amino acid sequences could be deter-
mined and subsequently compared with ABLV and CVS-11.
More samples neutralized ABLV than CVS-11, suggesting
that the Lyssavirus responsible for the induction of antibodies
in these bats might be more similar to ABLV than CVS-11,
while still being a member of phylogroup I. Repeating the
RFFIT assays with a challenge virus from phylogroup II, such
as MOKV or LBV, could have tested this hypothesis further.
Although it is possible that we might have been able to demon-
strate some cross-reactivity, a finding of greater neutralization
activity against MOKV (compared with what was found
against ABLV) would not be expected since all known phylo-
group II viruses have a rather limited geographic distribution
in Africa. In addition to the more widespread distribution of
phylogroup I lyssaviruses, the small quantities of available bat
sera precluded repeated RFFIT testing with an additional chal-
lenge virus such as MOKV.
The strict case definition used in the interpretation of the
RFFIT assays resulted in the identification of 22 positive bat
sera. As noted in the results of the second analysis, for which a
lower threshold for positivity was used, additional bat sera that
had 75% to 89% neutralization also had progressively decreas-
ing neutralization at increasing dilutions, a finding similar to
that for the 22 positive samples that met the strict case defini-
tion. Thus, we may have slightly underestimated the actual
prevalence of anti-Lyssavirus  antibody in these bat popula-
tions. Reduction in infectious centers by 90% compared with
the positive control provided a conservative estimate of the
prevalence of anti-Lyssavirus neutralizing antibodies. Previous
studies have used a cutoff as low as 50% neutralization for the
interpretation of data (21). Although the number of positive
bat sera more than doubled when the broader case definition
was used, no change in the results of the analysis of patterns of
seropositivity by location or type of bat was evident. In addi-
tion, independent of the cutoff point used, the peak antibody
measurement was approximately 0.6 IU/mL. Most of the other
positive specimens had approximately 0.3 IU/L. Many com-
mercial laboratories report serum samples with ‡0.5 IU/mL of
antibody as a positive test. However, the 0.5 IU/mL value was
established as an arbitrary standard by reference laboratories
as evidence above background for the detection of the induc-
tion of RABV-neutralizing antibodies in humans after receipt
of multiple doses of high-potency rabies vaccines (22). No
accepted standard for naturally occurring infections among
wildlife exists. 
On the basis of the 9.5% prevalence of neutralizing anti-
bodies, it is not surprising that all brain samples studied
showed no evidence of RABV antigen by DFA in these
Table 2. All bats caught on five islands in the Philippines and screened for neutralizing antibodies against Australian bat lyssavirus at a 1:10 
serum dilution
Bat species Island of origin








Scotophilus kuhlii 62 1
Cynopterus brachyotis 1
Eonycteris spelaea 1
Macroglossus minimus 1 2 1
Ptenochirus jagori 8
Pteropus hypomelanus 14
Rousettus amplexicaudatus 21 28 1
Table 3. All bats caught on four islands in the Philippines positive for 
neutralizing antibodies against Australian bat lyssavirus at a 1:10 
serum dilution
Bat species Island of origin
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clinically normal bats. Most studies of healthy bats have found
a low prevalence of active infection, usually <1% (21). As
would be expected, previous surveys of healthy bats in other
parts of the world have shown that the prevalence of RABV-
neutralizing antibodies is usually considerably higher than the
prevalence of active infection, as indicated by positive DFA
results for brain tissue. In a study of asymptomatic Mexican
free-tailed bats from a single dense cave population in New
Mexico, 69% of the bats had neutralizing antibodies, but only
0.5% had active infection demonstrated by DFA (21). A report
from the Caribbean described a 40.5% seroprevalence of
RABV-neutralizing antibodies among healthy and ill bats, but
only 1 bat, which had been submitted as an ill-appearing rabies
suspect, had active infection (23). Assuming a ratio of sero-
prevalence to active infection of approximately 100:1 in
healthy populations of bats, based on the seroprevalence of
9.5% demonstrated in this study, one would have needed to
test at least 1,052 normal bats to detect one case of active viral
infection by DFA. Such further studies should be focused on
species of bats such as M. schreibersi and in locations with the
highest prevalence of neutralizing antibodies. Ideally, if a
large stable colony of such bats could be identified, surveil-
lance among sick and dying bats could be conducted. Such a
study would increase the likelihood of obtaining a virus isolate
and would minimize the potential adverse impact on the bat
populations from oversampling large numbers of otherwise
healthy bats. Similarly, the routine virus variant typing of
human and domestic animal rabies cases in the Philippines and
throughout Southeast Asia will provide basic epidemiologic
information on the prevalence of different RABV isolates and
enhance the likelihood of discovery of any new lyssaviruses
affecting the populations in these regions. 
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